Sharon Worcester, MA

News

Debate: Should CAR T Best Be Used in Early MM Relapse?

Author:: Sharon Worcester, MA

Publish date: September 12, 2024

When patients with myeloma relapse, blood cancer specialists disagree on whether and when to treat them with CAR T-cell therapy.

News

To Choose the Best First-line Drug for CML, Consider Efficacy and Cost

Author:: Sharon Worcester, MA

Publish date: September 6, 2024

For treatment value, imatinib remains the CML gold standard: a generic, second-generation TKI that helps improve treatment-free remission rates.

News

Jeffrey Weber, MD, PhD, Giant of Cancer Care, Dies

Author:: Sharon Worcester, MA

Publish date: August 21, 2024

He was a principal investigator on many studies, including pivotal clinical drug trials in melanoma.

News

FDA Approves Axatilimab for Chronic GVHD

Author:: Sharon Worcester, MA

Publish date: August 15, 2024

For children and adults with graft versus host disease, a first-in-class monoclonal antibody axatilimab has received FDA approval.

News

FDA Approves First Targeted Therapy for Gliomas With IDH Mutations

Author:: Sharon Worcester, MA

Publish date: August 7, 2024

The approval of vorasidenib marks “one of the biggest advances in low-grade glioma in more than two decades.”

News

FDA Expands Dostarlimab-gxly Approval for Endometrial Cancer

Author:: Sharon Worcester, MA

Publish date: August 2, 2024

‘This is the only immuno-oncology treatment regimen that has shown a statistically significant overall survival benefit for the full patient popula...

News

FDA Expands Darzalex Faspro Indication in Myeloma

Author:: Sharon Worcester, MA

Publish date: August 2, 2024

The approval followed priority review and was based on efficacy and safety findings from the open-label PERSEUS trial.

News

FDA Expands Darzalex Faspro Indication in Myeloma

Author:: Sharon Worcester, MA

Publish date: August 1, 2024

Darzalex Faspro was approved by the Food and Drug Administration for treating transplant-eligible patients newly diagnosed with myeloma.

News

Two Soliris Biosimilars Approved for PNH in the US

Author:: Sharon Worcester, MA

Publish date: July 24, 2024

For treatment of two rare blood disorders, the FDA has just greenlighted two monoclonal antibodies.

News

AML: Shorter Venetoclax Course Shows Promise for Some

Author:: Sharon Worcester, MA

Publish date: July 1, 2024

A 7+7 course of azacitidine and venetoclax shows promise versus standard therapy for certain patients with acute myeloid leukemia.

News

B-ALL: New Findings Confirm Efficacy of CAR T Product

Author:: Sharon Worcester, MA

Publish date: June 28, 2024

Fresh research presented at ASCO 2024 establishes obe-cel, a CAR T product, as a standard-of-care treatment for adults with R/R B-ALL.

News

ESOPEC: FLOT Bests CROSS in Resectable Esophageal Cancer

Author:: Sharon Worcester, MA

Publish date: June 26, 2024

Study results settle a long-standing debate about whether chemotherapy with FLOT before and after surgery, or neoadjuvant radiation plus CROSS foll...

News

FDA Approves Adagrasib for KRAS G12C–Mutated CRC

Author:: Sharon Worcester, MA

Publish date: June 25, 2024

The agent is the first KRAS inhibitor approved for CRC.

News

FDA Expands Pembrolizumab Approval for Endometrial Cancer

Author:: Sharon Worcester, MA

Publish date: June 19, 2024

The indication for pembrolizumab was expanded to include the use of the targeted immunotherapy agent plus chemotherapy followed by single-agent pem...

News

One Patient Changed This Oncologist’s View of Hope. Here’s How.

Author:: Sharon Worcester, MA

Publish date: June 19, 2024

“How we think about hope directly influences patient care,” according to a professor of clinical medicine at Weill Cornell Medicine in New York Cit...